Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: REC-1245 · Unresectable, Locally Advanced, or Metastatic Cancer Primary and study completion pushed from Oct 30, 2028 to Jul 2029 Recursion Pharmaceuticals Inc.Phase 1/2 NCT06678659
  2. Notable: SNH-119014 · Non-transfusion-dependent Thalassemia (NTDT) Primary completion pushed from Mar 29, 2027 to Sep 30, 2027 ScinnoHub Pharmaceutical Co., Ltd.Phase 2 NCT07579949
  3. Notable: Abemaciclib and Elacestrant · Brain Metastasis Due to ER+/HER-2- Breast Cancer Primary completion pushed from Dec 2026 to Aug 2027 Stemline Therapeutics, Inc.Phase 1/2 NCT05386108
  4. Notable: Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old Primary completion pushed from Jun 2026 to Jun 2027 POLYSAN Scientific & Technological Pharmaceutical CompanyNot specified NCT07066540
  5. Notable: (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study Primary completion pushed from Aug 2026 to Aug 2027 Recross Cardio, Inc.Not applicable NCT07172464
  6. Notable: Efficiency of Cytoflavin, · Ischemic Stroke Not Receiving Reperfusion Therapy Primary completion pushed from Sep 30, 2025 to Jun 1, 2027 POLYSAN Scientific & Technological Pharmaceutical CompanyNot specified NCT06514976
  7. Notable: Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time · Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Primary and study completion pushed from Mar 31, 2031 to Jun 30, 2034 Children's Oncology GroupPhase 3 NCT07466316
  8. Notable: STIMIT Activator 1 IDE Study Primary completion pushed from Apr 2026 to Jan 2027 Stimit AGNot applicable NCT05883163
  9. Notable: MyoTrain System in a Population · Trans-radial Limb Loss Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027 Infinite Biomedical TechnologiesNot applicable NCT05888428
  10. Notable: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Primary completion pushed from Jul 1, 2027 to Feb 1, 2028 Swiss GO Trial GroupPhase 3 NCT04111978
  11. Notable: SA of the Supira System for HRPCI Primary completion pushed from Apr 30, 2025 to Feb 6, 2026 Supira MedicalNot applicable NCT05864248
  12. Notable: KPAP Adherence Crossover Study Primary completion pushed from Dec 1, 2026 to Dec 1, 2027 SleepRes Inc.Not applicable NCT06413134
  13. Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 National Cancer Institute (NCI)Phase 2 NCT06390865
  14. Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 National Cancer Institute (NCI)Phase 2 NCT06385496
  15. Notable: Antibiotic Prophylaxis in Rhinoplasty Primary completion pushed from Dec 20, 2026 to Dec 20, 2027 Stanford UniversityPhase 3 NCT04194216
  16. Notable: LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) Primary completion pushed from Nov 6, 2026 to Dec 5, 2027 University Hospital, AngersNot applicable NCT06939322
  17. Notable: Alleviating Carbohydrate Counting · Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide Primary and study completion pushed from Jan 2027 to Dec 2027 McGill University Health Centre/Research Institute of the McGill University Health CentrePhase 2/3 NCT06387199
  18. Notable: Project: Every Child for Younger · Cancer Primary and study completion pushed from Dec 31, 2030 to Dec 31, 2032 Children's Oncology GroupNot specified NCT02402244
  19. Notable: Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia Primary and study completion pushed from Dec 2026 to Dec 2027 Oregon Health and Science UniversityPhase 4 NCT07293728
  20. Notable: Treatment of Language Impairment in Young · Autism Spectrum Disorder With Leucovorin Calcium Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027 Southwest Autism Research & Resource CenterPhase 2 NCT04060017
  21. Notable: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy · B Acute Lymphoblastic Leukemia Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028 M.D. Anderson Cancer CenterPhase 2 NCT02877303
  22. Notable: Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Primary completion pushed from Dec 30, 2026 to Dec 31, 2027 Dana-Farber Cancer InstitutePhase 2 NCT06677190
  23. Notable: Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Primary completion pushed from Oct 18, 2027 to Oct 18, 2029 Nantes University HospitalPhase 2 NCT06252870
  24. Notable: Post-Transplant Cyclophosphamide, Bortezomib and Abatacept · Graft-versus-Host-Disease (GvHD) Primary completion pushed from Aug 2026 to Nov 2027 Northwell HealthPhase 1/2 NCT05289167
  25. Notable: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Primary completion pushed from Oct 15, 2028 to May 15, 2029 Shanxi Province Cancer HospitalPhase 1/2 NCT07486648